{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:05:21Z","timestamp":1790877921253,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xkme.2026.101474","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:52:28Z","timestamp":1784217148000},"page":"101474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers to Use of Cardio-Kidney Protective Medications in Chronic Kidney Disease: Results of a Nephrology Provider Survey"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-0454","authenticated-orcid":false,"given":"Melanie R.","family":"Weltman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Marie U.","family":"Lavenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret F.","family":"Zupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-1468","authenticated-orcid":false,"given":"Manisha","family":"Jhamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4S","key":"10.1016\/j.xkme.2026.101474_bib1","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2026.101474_bib2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"10S","key":"10.1016\/j.xkme.2026.101474_bib3","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2025ejx8sf08","article-title":"National trends in use of CKD guideline-directed medical therapies [abstract TH-PO0382]","volume":"36","author":"Adhikari","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101474_bib4","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1681\/ASN.0000000000000473","article-title":"Stop sitting on our RAASes: get moving with the most effective care for our patients","volume":"35","author":"Lafayette","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101474_bib5","article-title":"Cardio Metabolic Survey investigators. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.xkme.2026.101474_bib6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/imj.16440","article-title":"General physicians\u2019 perspectives on SGLT2 inhibitors for heart failure","volume":"54","author":"Teng","year":"2024","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.xkme.2026.101474_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/cd22-0100","article-title":"Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study","volume":"41","author":"Yaseen","year":"2023","journal-title":"Clin Diabetes"},{"issue":"3","key":"10.1016\/j.xkme.2026.101474_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/j.ajkd.2025.09.024","article-title":"Optimizing comprehensive medication management in CKD: an opportunity to integrate pharmacists in the kidney care team","volume":"87","author":"Hudson","year":"2026","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101474_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","article-title":"Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community","volume":"144","author":"Nelson","year":"2021","journal-title":"Circulation"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:33:03Z","timestamp":1790875983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526002360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2590059526002360"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101474","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to Use of Cardio-Kidney Protective Medications in Chronic Kidney Disease: Results of a Nephrology Provider Survey","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101474"}}